<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-04-07">7 April 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>PhD</roleName><forename type="first">Vincenzo</forename><surname>Musolino</surname></persName>
							<email>v.musolino@unicz.it</email>
							<affiliation key="aff0">
								<orgName type="department">Institute of Research for Food Safety and Health (IRC-FSH)</orgName>
								<orgName type="institution">University of Catanzaro &apos;Magna Graecia&apos;</orgName>
								<address>
									<settlement>Catanzaro</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Palus</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="institution">University Medical Center Göttingen (UMG)</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anika</forename><surname>Tschirner</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Applied Cachexia Research</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="institution">Charité Medical School</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cathleen</forename><surname>Drescher</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="institution">University Medical Center Göttingen (UMG)</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Micaela</forename><surname>Gliozzi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Research for Food Safety and Health (IRC-FSH)</orgName>
								<orgName type="institution">University of Catanzaro &apos;Magna Graecia&apos;</orgName>
								<address>
									<settlement>Catanzaro</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cristina</forename><surname>Carresi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Research for Food Safety and Health (IRC-FSH)</orgName>
								<orgName type="institution">University of Catanzaro &apos;Magna Graecia&apos;</orgName>
								<address>
									<settlement>Catanzaro</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cristiana</forename><surname>Vitale</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Centre for Clinical and Basic Research</orgName>
								<orgName type="institution">IRCCS San Raffaele Pisana</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carolina</forename><surname>Muscoli</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Research for Food Safety and Health (IRC-FSH)</orgName>
								<orgName type="institution">University of Catanzaro &apos;Magna Graecia&apos;</orgName>
								<address>
									<settlement>Catanzaro</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">Centre for Clinical and Basic Research</orgName>
								<orgName type="institution">IRCCS San Raffaele Pisana</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfram</forename><surname>Doehner</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Center for Stroke Research</orgName>
								<orgName type="department" key="dep2">Charité Medical School</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Von Haehling</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="institution">University Medical Center Göttingen (UMG)</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="institution">University Medical Center Göttingen (UMG)</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vincenzo</forename><surname>Mollace</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Research for Food Safety and Health (IRC-FSH)</orgName>
								<orgName type="institution">University of Catanzaro &apos;Magna Graecia&apos;</orgName>
								<address>
									<settlement>Catanzaro</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">Centre for Clinical and Basic Research</orgName>
								<orgName type="institution">IRCCS San Raffaele Pisana</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jochen</forename><surname>Springer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="institution">University Medical Center Göttingen (UMG)</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Institute of Research for Food Safety and Health (IRC-FSH)</orgName>
								<orgName type="institution">University of Catanzaro Magna Graecia</orgName>
								<address>
									<settlement>Catanzaro</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-04-07">7 April 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">02DEC9FBBF387A4629C79AECFF04EDCB</idno>
					<idno type="DOI">10.1002/jcsm.12116</idno>
					<note type="submission">Received: 16 September 2015; Accepted: 24 February 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:09+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Cancer cachexia</term>
					<term>Heart failure</term>
					<term>Cardiac wasting</term>
					<term>Autophagy</term>
					<term>Body composition</term>
					<term>Megestrol acetate</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background Cachexia is a complex metabolic syndrome associated with cancer.</s><s>One of the features of cachexia is the loss of muscle mass, characterized by an imbalance between protein synthesis and protein degradation.</s><s>Muscle atrophy is caused by the hyperactivation of some of the main cellular catabolic pathways, including autophagy.</s><s>Cachexia also affects the cardiac muscle.</s><s>As a consequence of the atrophy of the heart, cardiac function is impaired and mortality is increased.</s><s>Anticachectic therapy in patients with cancer cachexia is so far limited to nutritional support and anabolic steroids.</s><s>The use of the appetite stimulant megestrol acetate (MA) has been discussed as a treatment for cachexia.</s></p><p><s>Methods In this study the effects of MA were tested in cachectic tumour-bearing rats (Yoshida AH-130 ascites hepatoma).</s><s>Rats were treated daily with 100 mg/kg of MA or placebo starting one day after tumour inoculation, and for a period of 16 days.</s><s>Body weight and body composition were assessed at baseline and at the end of the study.</s><s>Cardiac function was analysed by echocardiography at baseline and at day 11.</s><s>Locomotor activity and food intake were assessed before tumour inoculation and at day 11.</s><s>Autophagic markers were assessed in gastrocnemius muscle and heart by western blot analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Treatment with 100 mg/kg/day MA significantly attenuated the loss of body weight (À9 ± 12%, P &lt; 0.05) and the wasting of lean and fat mass (À7.0 ± 6% and À22.4 ± 3 %, P &lt; 0.001 and P &lt; 0.05, respectively).</s><s>Administration of 100 mg/kg/day MA significantly protected the heart from general atrophy (633.8 ± 30 mg vs. placebo 474 ± 13 mg, P &lt; 0.001).</s><s>Tumour-bearing rats displayed cardiac dysfunction, as indicated by the significant impairment of the left ventricular ejection fraction, the left ventricular fractional shortening, the stroke volume, the end dyastolic volume, and the end systolic volume.</s><s>In contrast, MA significantly improved left ventricular ejection fraction, left ventricular fractional shortening, and left ventricular end systolic volume.</s><s>Western blotting analysis showed an upregulation of the autophagic pathway in the gastrocnemius and hearts of the placebo-treated tumour-bearing rats.</s><s>Treatment with MA, however, was able to modulate the autophagic markers (e.g.</s><s>Beclin-1, p62, TRAF6, and LC3) in the gastrocnemius and in the hearts of tumourbearing rats.</s><s>Most importantly, 100 mg/kg/day MA reduced mortality [hazard ratio (HR): 0.44; 95%CI: 0.20-1.00;</s><s>P = 0.0486].</s></p><p><s>Conclusions Megestrol acetate improved survival and reduced wasting through a marked downregulation of autophagy, occurring in both skeletal and heart muscle, the latter effect leading to a significant improvement of cardiac function.</s><s>Our data suggest that MA might represent a valuable strategy to counteract the development of cancer cachexia-induced cardiomyopathy.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Cachexia is a complex metabolic disorder which has been shown to occur in late stages of chronic disease including cancer, characterized by involuntary weight loss caused by an ongoing wasting of skeletal muscle with or without loss of adipose tissue. <ref type="bibr" target="#b0">1</ref> In particular, cancer cachexia is a predictor of poor quality of life, poor treatment response, increased chemotherapy toxicity, and higher mortality. <ref type="bibr" target="#b1">2</ref></s><s>Cachexia affects 50-80% of patients with cancer and is responsible for 30% of cancer deaths. <ref type="bibr" target="#b2">3</ref></s><s>enerally, loss of muscle mass can be because of a decreased rate of protein synthesis, an increased rate of protein degradation or both.</s><s>However, there is a general consensus that cancer cachexia is essentially because of a sustained proteolysis. <ref type="bibr" target="#b3">4</ref></s><s>eight loss not only involves skeletal muscle and fat tissue but multiple organs, including the heart.</s><s>Although heart atrophy and functional cardiac abnormalities have been described in patients with cancer in the late sixties <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6</ref> and even though the heart, like the skeletal muscle, is a striated muscle, the effects of cancer cachexia on cardiac atrophy and function have been undervalued for a long time.</s><s>]<ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> However, the process underlying cardiac atrophy in patients with cancer cachexia is still a matter of debate.</s><s>The compromised heart function observed in cancer cachexia experimental models seems to be related to cardiac alterations including marked fibrosis and loss of contractile protein such as troponin I and myosin heavy chain. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b10">11</ref></s><s>2]<ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> However, UPS is not the only proteolitic pathway that is activated during cachexia.</s><s>The activation of autophagy-lysosomal pathway has been proposed as well. <ref type="bibr" target="#b14">15</ref></s><s>Interestingly, the UPS and autophagy may be coordinated to augment protein degradation. <ref type="bibr" target="#b15">16</ref></s><s>umour necrosis factor receptor-associated factor 6 (TRAF6) is an adapter protein for toll like receptor-mediated nuclear factor-κB signalling pathway activation that induces the production of pro-inflammatory cytokines. <ref type="bibr" target="#b16">17</ref></s><s>It is formerly known as a E3 ubiquitine ligase, but it has been reported to play an important role in coordinating the activation of autophagy and UPS in atrophying skeletal muscles. <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19</ref></s><s>utophagy is a highly conserved lysosome-driven degradation pathway of cellular constituents, normally activated at basal level to maintain cell homeostasis.</s><s>Emerging data clearly show that induction of autophagy occurs in the skeletal muscle and in the heart in different experimental models of cancer cachexia and that it strongly contributes to the pathogenesis of muscle wasting. <ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref></s><s>Whether autophagy is also modulated in cachectic patient is subject to debate.</s><s>Some reports showed that autophagy is induced in muscle biopsies of patients with lung and oesophageal cancer, <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b22">23</ref> but an earlier report, which investigated some biological markers in patients with cachexia associated with either chronic obstructive pulmonary disease or lung cancer, showed that autophagy is significantly increased only in the cachectic skeletal muscle of patients with chronic obstructive pulmonary disease <ref type="bibr" target="#b23">24</ref> .</s></p><p><s>Loss of appetite (i.e.</s><s>anorexia) is frequent in patients with cachexia and is associated with poor prognosis and reduced quality of life.</s><s>Moreover, loss of appetite is a multifactorial event that includes the increased expression of proinflammatory cytokines such as interleukin (IL)-1, IL-6, tumour necrosis factor or interferon-γ, <ref type="bibr" target="#b24">25</ref> which have been shown to have effects on peripheral metabolic pathways as lipolysis, proteolysis as well as on hypothalamic appetite regulation. <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27</ref></s><s>However, none of the nutritional strategies so far proposed for the treatment of cancer cachexia has been sufficient enough to reverse the syndrome.</s></p><p><s>Megestrol acetate (MA) is a synthetic, orally active derivative of the hormone progesterone, originally synthesized in 1963 as a contraceptive drug. <ref type="bibr" target="#b27">28</ref></s><s>It was used in the treatment of breast cancer and later in the treatment of endometrial cancer.</s><s>It was approved in the USA and in several European countries for the treatment of the anorexia-cachexia syndrome. <ref type="bibr" target="#b28">29</ref></s><s>]<ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref> Although many reports suggest that the weight gain is only because of an increase in fat mass, <ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref> a recent randomized phase III clinical trial showed that MA treatment positively affects muscle mass and performance, <ref type="bibr" target="#b36">37</ref> probably because of reduced muscle wasting.</s><s>Indeed, it has been demonstrated that MA is able to reduce the rate of protein degradation in incubated isolated skeletal muscle through a mechanism based on the inhibition of the UPS. <ref type="bibr" target="#b37">38</ref></s><s>Moreover, MA treatment seems to lower humoral factors implicated in cachectic response, such as cytokines. <ref type="bibr" target="#b38">39</ref></s><s>Nevertheless, the potential for MA in the treatment of cachexia-induced cardiomiopathy remains to be better clarified.</s></p><p><s>The aim of the present investigation was to assess the effects of MA on body weight, body composition, cardiac function, and quality of life as well as survival in a rat Yoshida AH-130 hepatoma cancer cachexia model.</s><s>Further, we also extensively investigated its efficacy in modulating the autophagic catabolic pathway in the gastrocnemius and in the hearts of tumour-bearing rats.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals</head><p><s>Male Wistar Han rats (Harlan Laboratories, Rossdorf, Germany) of 8 weeks of age and weight of 199.8 ± 2.8 g were kept under standard laboratory conditions in a specific-pathogen-free animal facility and maintained at 22 ± 2°C with alternating 12 h light-dark cycle and free access to food and water.</s><s>All the experimental procedures were performed in accordance with the European Commission guidelines for the animals used for scientific purposes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>Rats were randomized into two groups to be injected with either Yoshida 10 8 AH-130 hepatoma cells (n = 21) or saline (n = 11, sham) into the peritoneum.</s><s>Tumour-bearing rats were further divided to be treated with placebo (n = 11) or with 100 mg/kg/day MA (n = 10).</s><s>All treatments were given via gavage once daily over a period of maximum 16 days.</s><s>Treatment with MA or placebo started one day after tumour inoculation.</s><s>All operators involved in the study were blinded to treatment allocation.</s><s>One day before tumour inoculation, baseline body weight, body composition, and echocardiographic analysis were assessed.</s><s>Cardiac function was analysed again on day 11.</s><s>Body composition and body weight were recorded on day 16 or the day of the euthanasia if the animals had to be sacrificed for ethical reasons.</s><s>At the end of the study and for each tumour-bearing animals, the tumour was harvested from the peritoneum and its volume evaluated.</s><s>Tumour cell number was determined using a Neubauer chamber.</s><s>Organs and tissues were rapidly removed, weighed, and immediately frozen in liquid nitrogen.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body composition analysis</head><p><s>Total body fat, lean mass, and body fluids were measured using the nuclear magnetic resonance spectroscopy device EchoMRI-700 TM (Echo Medical System, Houston, TX, USA).</s><s>Each rat was allocated in a tube for the measurement, which takes 90 s.</s><s>The analysis of the body structures is based on nuclear magnetic resonance, which measures the resonance of magnetic active nuclei in the tissues. <ref type="bibr" target="#b39">40</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Spontaneous activity and food intake</head><p><s>Animals were housed individually, and spontaneous movement was recorded by an infrared monitoring system (Supermax, Muromachi, Tokyo, Japan) over a 24 h period.</s><s>Food intake was also recorded during this period. <ref type="bibr" target="#b40">41</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Echocardiographic analysis</head><p><s>Echocardiographic analyses were performed using the highresolution Vevo 770 system (VisualSonics Inc, Toronto, Canada), which was described previously. <ref type="bibr" target="#b41">42</ref></s><s>Rats were anaesthetized with 1.5% isoflurane and laid in supine position on a heated surface to maintain body temperature and with all legs taped to ECG electrodes.</s><s>All hair was removed from the chest using an electrical clipper prior to shave the animals with a chemical depilatory agent.</s><s>Recordings were made in Bmode and M-mode to assess functional parameters, cardiac function, and dimensions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protein extraction and sodium dodecyl sulfate polyacrylamide gel electrophoresis western blot</head><p><s>Approximately 50 mg of heart and gastrocnemius muscle were separately homogenized in 500 μL ice-cold lysis buffer (20 mM Tris-HCl pH 7.5; 150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1% Triton X-100; 2,5 mM Na 4 P 2 O 7 ; 20 mM NaF; 1 mM dithiothreitol; 1 mM Na 3 VO4; 1 mM β-glycerophosphate; and 10 μL/mL freshly added protease and phosphatase inhibitor cocktails), centrifuged at 14 000 × g for 20 min at 4°C and supernatant was collected.</s><s>A total of 20 μL of the supernatant was used to determine the total protein concentration by Bradford assay (Biorad, Hercukes, California, USA) using bovine serum albumin as a standard.</s><s>Proteins were heat denatured for 5 min at 95°C in sampleloading buffer (500 mM Tris/HCl, pH 6.8; 30% Glycerol; 10% sodium dodecyl sulfate; 5% β-mercaptoethanol; and 0024% bromophenol blu), and 30 μg of protein lysate was resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (GE Healthcare, Little Chalfont, UK).</s><s>Membranes were blocked with Tris/HCl (pH 7.6) containing 0.1% Tween 20 and 5% BSA for 2 h and incubated overnight at 4°C with shaking with the following primary antibodies: Beclin-1 (3738, Cell Signaling Technology, Boston, USA), ATG12 (4180, Cell Signaling Technology, Boston, USA), LC3B (NB100-2220, Novus Biologicals, Littleton, USA), SQSTM1/p62 (5114, Cell Signaling Technology, Boston, USA), TRAF6 (ab33915, Abcam, Cambridge, UK), and GAPDH (G9545, Sigma-Aldrich, St. Louis, Missouri, USA).</s><s>Membranes were then washed in TBS (pH 7.6) with 0.1% Tween-20 and incubated with a fluorescent-conjugated IgG secondary antibody (IRDye 680RD, Fisher Scientific International Inc., Hampton, New Hampshire, USA) for 1 h at RT with shaking.</s><s>Immunoblot scanning and analyses were performed using an imaging system (Odyssey Classic, LI-COR Biosciences, Lincoln, NE, USA).</s><s>Quantification of the bands was performed using the ImageJ software (NIH, Bethesda, Maryland, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Data were analysed with GraphPad PRISM 6.0 (GraphPad Software, Inc., La Jolla, CA, USA).</s><s>Results are shown as mean ± SEM.</s><s>Normality was tested using D'Agostino Pearson's test.</s><s>Normally distributed data were analysed by one way ANOVA followed by Tukey's test, while data without normal distribution were analysed using Kruskal-Wallis analysis of variance and subsequent Dunn's tests.</s><s>Survival was tested by Cox-proportional hazard analysis, hazard ratio (HR), and 95% confidence interval (CI).</s><s>A P-value of &lt;0.05 was considered significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Megestrol acetate improves survival in cancer cachexia</head><p><s>To assess whether the treatment with MA could have a positive effect on the lifetime in case of cancer cachexia development, we analysed the survival of the animals.</s><s>Despite of the lack of statistically significant effect of MA treatment on tumour growth (2996 ± 222 × 10 6 and 2970 ± 538 × 10 6 in placebo and MA-treated animals, respectively), tumour-bearing rats treated with 100 mg/kg/day MA showed a better survival compared with placebo animals (HR: 0.44; 95%CI: 0.20-1.00;</s><s>P = 0.0486; Figure <ref type="figure">1</ref>)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Megestrol acetate reduces wasting in cancer cachexia</head><p><s>Baseline weight and body composition, i.e. lean and fat mass, were similar in all the randomized groups before tumour inoculation (P &gt; 0.2; Figure <ref type="figure" target="#fig_0">2(A-C</ref>)).</s><s>However, while tumourbearing rats treated with placebo lost 25 ± 6% of their initial body weight, non-tumour-bearing, or sham, animals gained 30.4 ± 2% (P &lt; 0.001; Figure <ref type="figure" target="#fig_0">2D</ref>).</s><s>Fat mass was reduced by 64.6 ± 1% in tumour-bearing rats treated with placebo compared with a gain of 55.4 ± 1% in sham animals (P &lt; 0.001; Figure <ref type="figure" target="#fig_0">2E</ref>).</s><s>Lean body mass was reduced by 26.1 ± 5% in the tumour-bearing rats treated with placebo, while a muscle mass gain of 27.5 ± 2% was observed in sham rats (P &lt; 0.001; Figure <ref type="figure" target="#fig_0">2F</ref>).</s><s>Treatment with 100 mg/kg/day MA significantly attenuated the loss of body weight (À9 ± 12%, P &lt; 0.05; Figure <ref type="figure" target="#fig_0">2D</ref>) and the wasting of fat mass and lean mass (À22.4 ± 3 and À7.0 ± 6% %, P &lt; 0.05 and P &lt; 0.001, respectively; Figures <ref type="figure" target="#fig_0">2E and 2F</ref>) in the tumour-bearing rats.</s></p><p><s>As expected, the tumour burden had a strong effect on the individual muscles and tissues.</s><s>The weights of the gastrocnemius muscle, soleus muscle, extensor digitalis longus muscle, and tibialis muscle were significantly lower in placebo-treated tumour-bearing rats compared with sham animal (P &lt; 0.001; Table <ref type="table" target="#tab_0">1</ref>).</s><s>Treatment with 100 mg/kg/day MA markedly increased the weights of mixed fibre type gastrocnemius muscle and tibialis, fast-twitch extensor digitalis longus muscle, and slowtwitch soleus muscle in the tumour-bearing animals (all P &lt; 0.001 vs. placebo; Table <ref type="table" target="#tab_0">1</ref>).</s><s>Moreover, white adipose tissue and brown adipose tissue were also afftected by tumour cachexia (both P &lt; 0.001 vs. sham; Table <ref type="table" target="#tab_0">1</ref>).</s><s>The treatment with 100 mg/kg/day MA increased the weight of epididymal white and brown intrascapular fat in tumour-bearing rats (P &lt; 0.01 vs. placebo, respectively; Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Figure <ref type="figure">1</ref> Kaplan-Meier survival curve and statistical analysis of survival of animals treated with 100 mg/kg/day megestrol acetate or placebo.</s><s>A high mortality was observed in the placebo group (85%), which was significantly reduced by 100 mg/kg/day megestrol acetate.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Indices of morbidity</head><p><s>Baseline 24 h spontaneous activity and food intake were similar in all groups (all P &gt; 0.2; Fig. <ref type="figure">S1</ref>).</s><s>Cachectic rats treated with placebo showed a decreased food intake and activity on day 11 (P &lt; 0.001 vs. sham; Figure <ref type="figure" target="#fig_1">3A</ref>).</s><s>Treatment with 100 mg/kg/day MA resulted in higher food intake compared with placebo (P &lt; 0.05; Figure <ref type="figure" target="#fig_1">3A</ref>) whilst no effect on activity was observed (Figure <ref type="figure" target="#fig_1">3B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Megestrol acetate improves tumour-induced cardiac dysfunction and heart wasting</head><p><s>Baseline echocardiography was similar in all groups before tumour inoculation (P &gt; 0.1; Table <ref type="table" target="#tab_0">S1</ref>).</s><s>On day 11, tumourbearing rats, treated with placebo, displayed an overall deterioration of cardiac function compared with baseline sham animals.</s><s>However, a number of parameters of cardiac function were improved by treatment with MA.</s><s>The left ventricular  ejection fraction (LVEF) was reduced in tumour-bearing rats treated with placebo compared with sham animals (58.7 ± 2% vs. sham 75.4 ± 2%, P &lt; 0.01; Figure <ref type="figure" target="#fig_2">4B</ref>).</s><s>Treatment with 100 mg/kg/day MA significantly improved LVEF (73.5 ± 5%, P &lt; 0.05 vs. placebo, Figure <ref type="figure" target="#fig_2">4B</ref>).</s><s>The left ventricular fractional shortening (LVFS) was also reduced in tumour-bearing rats treated with placebo in comparison to control animals (30.25 ± 1% vs. sham 51.6 ± 1%, P &lt; 0.001; Figure <ref type="figure" target="#fig_2">4C</ref>).</s><s>The treatment with 100 mg/kg/day MA improved significantly LVFS (49 ± 4.6%; P &lt; 0.001 vs. placebo; Figure <ref type="figure" target="#fig_2">4C</ref>).</s><s>The left ventricular stroke volume (LVSV), the end systolic volume (LVESV) and the end diastolic volume (LVEDV) were significantly impaired in tumour-bearing rats treated with placebo compared with sham animals (P &lt; 0.001 for LVSV, P &lt; 0.05 for LVESV and LVEDV vs. sham; Figure <ref type="figure" target="#fig_2">4D, 4E, and 4F</ref>).</s><s>Whereas the LVSV and the LVEDV were not improved in the MA-treated group, administration of 100 mg/kg/day MA was able to restore significantly the end systolic volume (66.5 ± 8.4 μL vs. placebo 98.4±7.6μL;</s><s>P &lt; 0.05; Figure <ref type="figure" target="#fig_2">4E</ref>).</s><s>At the end of the study, the average weight of the hearts of the tumour group treated with placebo was smaller compared with control rats (474 ± 13 mg vs. sham 776 ± 10 mg, P &lt; 0.001; Figure <ref type="figure" target="#fig_2">4A</ref>).</s><s>Moreover, cancer cachexia had profound effects on cardiac diameters.</s><s>For instance, a larger left ventricular internal diameter at end-systole (LVID sys) and a reduction of the left ventricular internal diameter at end-diastole (LVID dia) were observed in tumour-bearing rats treated with placebo compared with sham (P &lt; 0.01 and P &lt; 0.001 for LVID sys and LVID dia vs. sham, respectively; Figures <ref type="figure" target="#fig_2">4G and 4H</ref>).</s><s>Administration of 100 mg/kg/day MA significantly protected the heart from general atrophy (633.8 ± 30 mg vs. placebo 474 ± 13 mg, P &lt; 0.001; Figure <ref type="figure" target="#fig_2">4A</ref>) and from the loss of LV diameter in systole (2.9 ± 0.2 mm vs. placebo 3.8 ± 0.1 mm, P &lt; 0.01; Figure <ref type="figure" target="#fig_2">4G</ref>) and in diastole (5.8 ± 0.1 mm vs. placebo 4.5 mm, P &lt; 0.001; Figure <ref type="figure" target="#fig_2">4H</ref>).</s><s>Finally, a striking reduction of left ventricular mass and posterior wall thickness (LVPWT sys), in systole, was observed in the tumour group treated with placebo compared with sham rats (both P &lt; 0.01 vs. sham; Figure <ref type="figure" target="#fig_2">4I and  4L</ref>).</s><s>Treatment with 100 mg/kg/day MA significantly improved the value of the posterior wall thickness, in systole (2.75 ± 0.1 mm vs. placebo 2.3 mm, P &lt; 0.05; Figure <ref type="figure" target="#fig_2">4L</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Megestrol acetate downregulates autophagic catabolic pathway in the gastrocnemius muscle and in the heart of tumour-bearing rats</head><p><s>To assess the protective role exerted by MA in the muscle mass in the context of modulation of autophagic degradation, autophagic markers, in the gastrocnemius and in the heart of the tumour-bearing rats and in the control animals, were analysed.</s><s>Although ATG12-ATG5 and Beclin-1, which play an important role in the initial steps and in the formation of the autophagosome, were not upregulated in the gastrocnemius muscle of tumour-bearing rats treated with placebo compared with control animals (Figures <ref type="figure">5A and 5B</ref>), a significant increase of microtubule-associated protein 1 light chain 3B isoform I (LC3B-I) and its lipidated form LC3B-II was detected (both P &lt; 0.001 vs. sham; Figures <ref type="figure">5E and 5F</ref>).</s><s>In addition, the ratio of LC3B-II to LC3B-I was measured as a marker of LC3 cleavage and therefore activation of the autophagic pathway.</s><s>In the gastrocnemius, the LC3 ratio was increased in the tumour group treated with placebo compared with the control group (P &lt; 0.05 vs. sham, Figure <ref type="figure">5G</ref>).</s><s>Moreover, p62, as a marker of substrate sequestration into autophagosome, was assayed.</s><s>Levels of p62 were significantly higher (P &lt; 0.01; Figure <ref type="figure">5C</ref>) in the skeletal muscle of tumour-bearing rats treated with placebo than in sham rats.</s><s>In addition, levels of the protein TRAF6 were greater in the gastrocnemius muscle of  placebo-treated tumour-bearing rats than in sham rats (P &lt; 0.001; Figure <ref type="figure">5D</ref>).</s><s>Treatment with 100 mg/kg/day MA significantly reduced the autophagic markers in the gastrocnemius of the tumour-bearing rats.</s><s>Indeed, LC3 was downregulated in both forms as well as LC3B-II/LC3B-I ratio (P &lt; 0.001 for LC3B-I and LC3B-II, P &lt; 0.05 for LC3B-II/LC3B-I vs. placebo, respectively; Figure <ref type="figure">5E</ref>, 5F, and 5G).</s><s>Similarly, p62 levels were downregulated as a result of megesterol acetate treatment (P &lt; 0.05 vs. placebo; Figure <ref type="figure">5C</ref>).</s><s>Finally, TRAF6 protein levels demonstrated no significant difference between placebo and MA-treated tumour rats (Figure <ref type="figure">5D</ref>).</s><s>Heart ATG12-ATG5 complex levels were not significantly different between any groups.</s><s>However, heart Beclin-1 protein levels were significantly higher (P &lt; 0.05; Figure <ref type="figure" target="#fig_3">6B</ref>) in the tumour group treated with placebo compared with the sham group.</s><s>Treatment with 100 mg/kg/day MA significantly reduced Beclin-1 levels in the tumour-bearing rats (P &lt; 0.01 vs. placebo; Figure <ref type="figure" target="#fig_3">6B</ref>).</s><s>LC3B-I expression did not change in the hearts of the tumour-bearing rats treated with placebo (Figure <ref type="figure" target="#fig_3">6E</ref>), whereas LC3B-II levels were significantly elevated compared with sham animals (P &lt; 0.01; Figure <ref type="figure" target="#fig_3">6F</ref>).</s><s>The LC3 ratio was increased (P &lt; 0.001; Figure <ref type="figure" target="#fig_3">6G</ref>) in the tumour group treated with placebo compared with the control rats.</s><s>Administration of 100 mg/kg/day MA significantly reduced LC3B-I (P &lt; 0.01 vs. placebo; Figure <ref type="figure" target="#fig_3">6E</ref>), LC3B-II (P &lt; 0.001 vs. placebo; Figure <ref type="figure" target="#fig_3">6F</ref>), and the Figure <ref type="figure">5</ref> Megestrol acetate downregulates autophagy in the gastrocnemius muscle of tumour-bearing rats.</s><s>(A) ATG12-ATG5 and (B) Beclin were not upregulated in the gastrocnemius muscle of tumour-bearing rats treated with placebo compared with control animals.</s><s>(C) Levels of p62 were significantly higher in tumour-bearing rats treated with placebo than in sham rats.</s><s>Treatment with 100 mg/kg/day MA significantly downregulated p62 levels.</s><s>(D) TRAF6 levels were greater in placebo-treated tumour-bearing rats than in sham rats.</s><s>Protein levels were not downregulated as a result of megesterol acetate treatment.</s><s>(E) LC3B-I, (F) its lipidated form LC3B-II, and (G) the LC3 ratio were upregulated in placebo-treated tumour-bearing rats than in sham rats.</s><s>Treatment with 100 mg/kg/day MA significantly downregulated LC3 in both forms (LC3-II and LC3-II), as well as LC3B-II/LC3B-I ratio was downregulated.</s><s>The data are presented as mean ± SEM.</s></p><p><s>* :P &lt; 0.05, ** :P &lt; 0.01, *** :P &lt; 0.001 vs. sham; # :P &lt; 0.05, ### :P &lt; 0.001 vs. placebo.</s></p><p><s>Sham n À 11, placebo n À 11, 100 mg/kg/day megestrol acetate n À 10.</s></p><p><s>LC3B-II/LC3B-I ratio in the hearts of the tumour group (P &lt; 0.05 vs. placebo; Figure <ref type="figure" target="#fig_3">6G</ref>).</s><s>In addition, p62 heart expression was increased in the placebo-treated tumour group compared with sham animals (P &lt; 0.01; Figure <ref type="figure" target="#fig_3">6C</ref>), whereas 100 mg/kg/day MA significantly reduced p62 accumulation (P &lt; 0.05 vs. placebo; Figure <ref type="figure" target="#fig_3">6C</ref>).</s><s>Although, heart TRAF6 expression had an increasing trend, which did not reach any statistical significance, in tumour-bearing rats of the placebo group compared with sham rats (Figure <ref type="figure" target="#fig_3">6D</ref>), administration of 100 mg/kg/day MA significantly downregulated the expression of TRAF6 in the tumour group (P &lt; 0.01 vs. placebo; Figure <ref type="figure" target="#fig_3">6D</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Tumour burden induces a severe wasting of skeletal muscle and fat tissue.</s><s>In the present work we have demonstrated that Yoshida hepatoma is also associated with a form of cachexia, which induces cardiomyopathy in rats.</s><s>In cancer cachexia, skeletal muscle and heart wasting are associated with an hyperactivation of autophagy. <ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref></s><s>We supported these data and, in addition, we demonstrated, for the first time, that MA downregulates autophagy in skeletal and heart muscle with a significant improvement of cardiac function.</s><s>Here, we show that MA attenuates the loss of body weight in the Yoshida AH-130 hepatoma cancer cachexia model without effecting tumour growth.</s><s>The AH-130 hepatoma rat model also develops a marked anorexia, <ref type="bibr" target="#b42">43</ref> a condition often associated with cachexia in humans. <ref type="bibr" target="#b0">1</ref> Previous reports have shown that intake of the drug resulted in an increased sense of appetite in rodents <ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b43">44</ref> and in humans. <ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref></s><s>The precise mechanism of action of MA is unknown, but its effect may be partially mediated by the neuropeptide Y, a potent centrally acting appetite stimulant. <ref type="bibr" target="#b44">45</ref></s><s>Food intake and spontaneous activity are recognized as good indicators of the quality of life in animals. <ref type="bibr" target="#b45">46</ref></s><s>n our study, treatment with MA had a positive effect on food intake, but it did not enhance physical performance, further supporting the previously described failure of MA to totally improve quality of life. <ref type="bibr" target="#b46">47</ref></s><s>Although, several evidences <ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref> indicate the occurrence of a benefit in body weight gain subsequently to MA treatment, this seems to correlate with an increase only in fat mass, <ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref> with a direct action on adipocyte differentiation. <ref type="bibr" target="#b47">48</ref></s><s>owever, other findings showed an increased bioavailability of IGF-I during MA treatment, which may contribute to the anabolic action of the drug on skeletal muscle in patients with advanced cancer <ref type="bibr" target="#b48">49</ref> and a reduction of the muscle wasting process through a mechanism based on the modulation of the UPS. <ref type="bibr" target="#b37">38</ref></s><s>Here, we show for the first time that MA may inhibit, to some extend, muscle atrophy by decreasing the catabolic pathway of autophagy.</s></p><p><s>Autophagy has been implicated in hearts and skeletal muscles wasting in several models of cancer cachexia. <ref type="bibr" target="#b49">50</ref></s><s>e also demonstrated the hyperactivation of autophagy in rats bearing Yoshida AH-130 hepatoma by changes occurring in the well-recognized biomarkers of this catabolic pathway.</s><s>In particular, we found MA-associated positive changes in Beclin-1, an inducer of the autophagosome formation, in LC3B-I to LC3B-II conversion, which was measured as a marker of autophagosome abundance, in p62, a marker of substrate sequestration and finally in TRAF6, an E3 ubiquitin ligase, involved in activation of autophagy and UPS in atrophying skeletal muscle. <ref type="bibr" target="#b18">19</ref></s><s>n particular, we found that in the skeletal muscle, autophagy was associated with increased LC3B lipidation and p62 accumulation, whereas no changes in ATG12-ATG5 or Beclin-1 levels were observed.</s><s>Levels of p62 usually inversely correlate with autophagic degradation, <ref type="bibr" target="#b50">51</ref> although our reports, and other studies clearly showed that this marker could also be increased in many atrophic conditions upon activation of autophagy. <ref type="bibr" target="#b14">15</ref></s><s>The scaffold protein p62 assumes a main role in recognition of ubiquitinylated proteins or depolarized mitochondria during selective autophagy; interestingly, it has been described that p62 can also deliver ubiquitinylated cargos to the proteasome. <ref type="bibr" target="#b51">52</ref></s><s>Looking for proteins that play a regulatory role in activation of signalling cascades related to muscle atrophy, TRAF6, might potentially be an upstream regulator for the activation of pathways involved in loss of muscle proteins in conditions of wasting. <ref type="bibr" target="#b18">19</ref></s><s>TRAF6 expression is increased in several models of muscle atrophy, including fasting and cancer, leading to downstream activation of major catabolic pathways in skeletal muscle, including autophagy. <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b52">53</ref></s><s>In accordance with these reports, in the gastrocnemius of the Yoshida AH-130 hepatoma model we found high levels of TRAF6.</s><s>Our evidence supports the hypothesis that TRAF6 could modulate the autophagy also in this model.</s><s>Although MA reduced skeletal muscle atrophy, modulating some steps of the complex autophagic pathway, the drug did not have a direct effect on TRAF6, at least in the gastrocnemius.</s></p><p><s>Cardiac atrophy has been described in several models of cancer cachexia. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref></s><s>Our results support and extend these data.</s><s>We indeed observed a reduction of the posterior wall thickness, LV mass, and total heart weight in cachectic rats, which are features of cardiac atrophy.</s><s>MA administration attenuated this wasting.</s><s>Although the exact pathways leading to cardiac wasting are not fully elucidated, our results support the idea that the catabolic signalling pathways activated in the skeletal muscle are responsible for the atrophy of the heart. <ref type="bibr" target="#b53">54</ref></s><s>n this scenario, autophagy has been proposed as the main catabolic pathway regulated in the heart, whereas UPS has a high basal activity. <ref type="bibr" target="#b54">55</ref></s><s>However, it is likely that the activation of the main proteolitic pathways may differ between cancer models since using the Yoshida AH-130 hepatoma model, increased UPS activity was previously described. <ref type="bibr" target="#b10">11</ref></s><s>n the basis of the observation in the skeletal muscle and consistent with our findings of decreased cardiac mass, we observed that the heart atrophy in Yoshida AH-130 was associated with elevated level of Beclin-1, p62, and LC3, suggesting that changes in cardiac mass is clearly associated with autophagy.</s><s>The results presented in our study clearly demonstrated that MA may inhibit atrophic mechanism, modulating autophagy also in the heart.</s><s>MA might reduced the expression of humoral factors involved in chronic inflammation and oxidative stress, and contributing to the activation of protein degradation in muscle. <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b49">50</ref></s><s>Although new studies are needed to better clarify these findings, we can further postulate that the decreased expression of TRAF6 in the hearts of cachectic rats treated with MA might be because of a reduction expression of pro-inflammatory cytokines, because TRAF6 suppression resulted in reduced IL-1β and IL-6 expression. <ref type="bibr" target="#b55">56</ref></s><s>Overall, cardiac atrophy is associated with a clear heart dysfunction because of tumour growth and cachexia in the Yoshida AH-130 model.</s><s>The cardiac parameters that we analysed in this study are signs for myocardial dysfunction, and they are similar to previous results. <ref type="bibr" target="#b56">57</ref></s><s>Although the cardioprotective effect of MA has not been described so far, treatment with the drug could significantly improve LVEF, and LVFS of the cachectic rats compared with the placebo group, and therefore, it may prevent the development of cancer cachexia-induced cardiomyopathy. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b56">57,</ref><ref type="bibr" target="#b57">58</ref></s><s>Cardiac remodelling is a clear event in tumour-bearing rats and mice. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b49">50</ref></s><s>Even though our study is lacking some histological evidences, adverse cardiac remodelling in tumour-bearing rats, i.e. the reduction of LVID dia and LVID sys, was significantly attenuated by MA treatment.</s><s>Protecting heart and its function seems to be crucial in cachexia. <ref type="bibr" target="#b10">11</ref></s><s>Cardiac function was dramatically improved by treatment with MA, and this is likely contributed to the survival benefits observed in our study.</s></p><p><s>In conclusion, our data show the action of MA, an appetite stimulant, on body weight and cardiac function in the well-known Yoshida AH-130 hepatoma rat model of cancer cachexia.</s><s>In particular, MA improved survival and reduced wasting through a marked downregulation of autophagy, occurring in both skeletal and heart muscles, the latter effect leading to a significant improvement of cardiac function.</s><s>Thus, our data suggest that MA might represent a valuable strategy to counteract the development of cancer cachexia-induced cardiomyopathy.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Effect of megestrol acetate treatment on body weight and body composition of the tumour-bearing rats.</s><s>The lost of body weight (D), fat mass (E), and lean mass (F) are presented as the absolute difference between baseline (A, B, and C) and after removal the tumour at the end of the study.</s><s>White bars: sham; black bars: placebo; gray bars: 100 mg/kg/day megestrol acetate.</s><s>The data are presented as mean ± SEM. *** : P &lt; 0.001 vs. sham, # :P &lt; 0.05, ### :P &lt; 0.001 vs. placebo.</s><s>Sham n À 11, placebo n À 11, 100 mg/kg/day megestrol acetate n À 10.</s></p></div></figDesc><graphic coords="5,69.73,114.97,454.60,323.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Effect of megestrol acetate treatment on (A) food intake and (B) spontaneous activity of tumour-bearing rats.</s><s>Activity was not affected by the treatment, while food intake was increased by 100 mg/kg/day megestrol acetate.</s><s>White bars: sham; black bars: placebo; gray bars: 100 mg/kg/day megestrol acetate.</s><s>The data are presented as mean ± SEM. *** :P &lt; 0.001, * P &lt; 0.05 vs. sham; # :P &lt; 0.05 vs. placebo.</s><s>Sham n À 11, placebo n À 11,</s></p></div></figDesc><graphic coords="6,140.77,114.97,312.41,162.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure 4 The effect of megestrol acetate on cardiac function and heart wasting of cachectic rats.</s><s>(A) At the end of the study, the weight of the heart in the tumour group treated with placebo was smaller compared with control rats.</s><s>Treatment with 100 mg/kg/day MA significantly protected the hearts from atrophy.</s><s>(B) Left ventricular ejection fraction and (C) left ventricular fractional shortening were reduced in tumour-bearing rats treated with placebo compared with sham animals.</s><s>Treatment with 100 mg/kg/day MA significantly improved left ventricular ejection fraction and left ventricular fractional shortening.</s><s>(D) The left ventricular stroke volume, (E) the left ventricular end systolic volume, and (F) the left ventricular end diastolic volume were significantly impaired in tumour-bearing rats treated with placebo compared with sham animals.</s><s>Administration of 100 mg/kg/day MA was able to improve significantly the left ventricular end systolic volume (E), whereas the left ventricular stroke volume and the left ventricular end diastolic volume were not improved (D and F).</s><s>(G) A larger left ventricular internal systolic diameter and (H) a reduction of the left ventricular internal diastolic diameter were observed in tumour-bearing rats treated with placebo compared with sham rats.</s><s>Treatment with 100 mg/kg/day MA significantly protected from the loss of left ventricular diameter in systole (G) and in diastole (H).</s><s>(I) A striking reduction of left-ventricular mass and left ventricular posterior wall thickness, in systole, was observed in the tumour group treated with placebo compared with sham rats.</s><s>Treatment with 100 mg/kg/day MA significantly improved the value of the posterior wall thickness, in systole.</s><s>The data are presented as mean ± SEM. * :P &lt; 0.05, ** :P &lt; 0.01, *** : P &lt; 0.001 vs. sham; # :P &lt; 0.05, ## :P &lt; 0.01, ### :P &lt; 0.001 vs. placebo.</s><s>Sham n À 11, placebo n À 11, 100 mg/kg/day megestrol acetate n À 10.</s></p></div></figDesc><graphic coords="7,129.26,214.98,335.44,460.29" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 6</head><label>6</label><figDesc><div><p><s>Figure6Megestrol acetate downregulates autophagy in the heart of tumour-bearing rats.</s><s>(A) ATG12-ATG5 complex levels were not different between any groups.</s><s>(B) Beclin-1 was significantly higher in the cachectic rats treated with placebo compared with the sham group.</s><s>Treatment with 100 mg/kg/ day MA significantly reduced Beclin-1 levels in the tumour-bearing rats.</s><s>(C) The p62 expression was increased in the placebo-treated tumour group compared with sham animals, whereas 100 mg/kg/day MA significantly reduced p62 accumulation.</s><s>(D) TRAF6 expression had an increasing trend, in the cachectic animals treated with placebo compared with sham rats.</s><s>Treatment with 100 mg/kg/day MA significantly downregulated the expression of TRAF6 in the tumour group.</s><s>(E) LC3B-I expression did not change in the hearts of the tumour-bearing rats treated with placebo, whereas (F) LC3B-II levels were significantly elevated compared with sham rats.</s><s>(G) The LC3 ratio was increased in the tumour group treated with placebo compared with the control rats.</s><s>Treatment with 100 mg/kg/day MA significantly reduced LC3B-I, LC3B-II levels and the LC3B-II/LC3B-I ratio of the cachectic animals.</s><s>The data are presented as mean ± SEM.* :P &lt; 0.05, ** :P &lt; 0.01, *** :P &lt; 0.001 vs. sham; # :P &lt; 0.05, ## :P &lt; 0.01, ### :P &lt; 0.001 vs. placebo.</s><s>Sham n À 11, placebo n À 11, 100 mg/kg/day megestrol acetate n À 10.</s></p></div></figDesc><graphic coords="9,54.94,174.96,484.82,374.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="4,178.81,465.68,236.45,239.41" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="8,55.56,154.94,482.66,372.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Tissues and muscles weight at the end of the study</s></p></div></figDesc><table><row><cell></cell><cell>Gastrocnemius (mg)</cell><cell>Soleus (mg)</cell><cell>EDL (mg)</cell><cell>BAT (mg)</cell><cell>WAT (mg)</cell></row><row><cell>Sham</cell><cell>1235 ± 37.9</cell><cell>96.9 ± 2.7</cell><cell>105.2 ± 3.1</cell><cell>250.2 ± 13.9</cell><cell>1281 ± 66.7</cell></row><row><cell>Placebo 100 mg/kg/day MA</cell><cell>736.7 ± 34.1*** 978.9 ± 48 ###</cell><cell>70.1 ± 1.6*** 90.1 ± 4.7 ###</cell><cell>62.9 ± 2.6*** 88.6 ± 4.8 ###</cell><cell>69.9 ± 3.4*** 165.6 ± 33.5 ##</cell><cell>191.5 ± 9.1*** 611.7 ± 148.7 ##</cell></row></table><note><p><s>EDL, extensor digitalis longus; WAT, white adipose tissue; BAT, brown adipose tissue.</s><s>***P &lt; 0.001 vs. sham.</s><s>## P &lt; 0.01.</s><s>### P &lt; 0.001 vs. placebo.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 555-566 DOI: 10.1002/jcsm.12116</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia, and Muscle. <ref type="bibr" target="#b58">59</ref></s><s> Musolino has received a grant from European Commission, European Social Fund and Regione Calabria (POR Calabria FSE 2007-2013); from PON03PE_00078_1 and PON03PE_00078_2.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>None declared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Online supplementary material</head><p><s>Supporting information may be found in the online version of this article.</s><s><ref type="table">S1</ref>.</s><s>Cardiac dimensions and function assessed before tumour inoculation</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cachexia: a new definition</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Argiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baracos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Guttridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jatoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lochs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Mitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muscaritoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Najand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rossi</forename><surname>Fanelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schambelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schuster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wolfe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="793" to="799" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prevalence, incidence and clinical impact of cachexia: facts and numbers-update</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="261" to="263" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cachexia as a major underestimated and unmet medical need: facts and numbers</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Lecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Jagoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baracos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Mitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="39" to="51" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The low incidence of terminal myocardial infarction and the reversibility of cardiac hypertrophy in cachexia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Wilens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Dische</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Henderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med Sci</title>
		<imprint>
			<biblScope unit="volume">253</biblScope>
			<biblScope unit="page" from="651" to="660" />
			<date type="published" when="1967">1967</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The cachetic heart. A clinico-pathologic, electrocardiographic and roentgenographic entity</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Burch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ansari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dis Chest</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="403" to="409" />
			<date type="published" when="1968">1968</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Asp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nishijima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Belury</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1321" to="1326" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Cardiac alterations in cancer-induced cachexia in mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nishijima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Asp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Stout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Reiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Belury</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="347" to="353" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Myocardial dysfunction in an animal model of cancer cachexia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Youtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Lucchesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Velten</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Sci</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="406" to="410" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hartman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Wirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Ruis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Möller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Köhrle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="2187" to="2196" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Prevention of liver cancer cachexia-induced cardiac wasting and heart failure</title>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haghikia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grzesiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kaschina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pötsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Von Websky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hocher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Latouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jaisser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Morawietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beadle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Thum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Földes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hilfiker-Kleiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Force</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="932" to="941" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Muscle protein waste in tumour-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garcia-Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Llovera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Carbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Lopez-Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Agell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tessitore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Baccino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argiles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="2367" to="2372" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>Role of the ATP-ubiquitin-dependent proteolytic pathway</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Increased muscle ubiquitin mRNA levels in gastric cancer patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bossola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muscaritoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bellantone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pacelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Busquets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Argilès</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Lopez-Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Civello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Baccino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rossi</forename><surname>Fanelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Doglietto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Regul Integr Comp Physiol</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="R1518" to="1523" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Hypercatabolism and hypermetabolism in wasting states</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Baracos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Clin Nutr Metab Care</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="237" to="239" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Autophagic degradation contributes to muscle wasting in cancer cachexia</title>
		<author>
			<persName><forename type="first">F</forename><surname>Penna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Costamagna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Camperi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fanzani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Chiarpotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cavallini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Baccino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="page" from="1367" to="1378" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sandri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="2121" to="2129" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">TRAF6 is a signal transducer for interleukin-1</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Takeuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kurama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Goeddel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">383</biblScope>
			<biblScope unit="page" from="443" to="446" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhatnagar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Panguluri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Darnay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">191</biblScope>
			<biblScope unit="page" from="1395" to="1411" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">TRAF6 coordinates the activation of autophagy and ubiquitinproteasome systems in atrophying skeletal muscle</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Autophagy</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="555" to="556" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Cosper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Leinwand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1710" to="1720" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Manne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Enos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Blough</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="2134" to="2140" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Jagoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Goodship</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Sci</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="353" to="361" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients</title>
		<author>
			<persName><forename type="first">N</forename><surname>Tardif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Klaude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lundell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thorell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rooyackers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1485" to="1492" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Puig-Vilanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lloreta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ausin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pascual-Guardia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Broquetas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Barreiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Free Radic Biol Med</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="91" to="108" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Malnutrition, anorexia and cachexia in cancer patients: a mini-review on pathogenesis and treatment</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nicolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Masoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pagani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Giampietro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carpi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Pharmacother</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="807" to="817" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Pancreatic cancer cachexia: a review of mechanisms and therapeutics</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Yaffee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Jamil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Physiol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">88</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Cachexia: pathophysiology and clinical relevance</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="735" to="743R" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Anti-ovulatory and other biological properties of megestrol acetate 17α-acetoxy-6 methyl pregna 4:6-diene-3:20-dione(B.D.H.1298)</title>
		<author>
			<persName><forename type="first">A</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Fellowes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Plummer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Reprod Fertil</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="331" to="346" />
			<date type="published" when="1963">1963</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">A new look at an old drug for the treatment of cancer cachexia: megestrol acetate</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argilés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Anguera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stemmler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="319" to="324" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Megestrol acetate for anorexia in patients with faradvanced cancer: a double-blind controlled clinical trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>De Conno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Martini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Zecca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Balzarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Venturino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Groff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Caraceni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1705" to="1709" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bruera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hagen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Spachynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Belzile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Summers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dulude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gallant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Prev Control</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="74" to="78" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Loprinzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Michalak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Schaid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mailliard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Athmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Tschetter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Hatfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Morton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="762" to="767" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bruera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Macmillan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kuehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Macdonald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1279" to="1282" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Feliu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>González-Barón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berrocal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Artal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ordóñez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Garrido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zamora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>García De Paredes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Montero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="436" to="440" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Megestrol acetate in patients with AIDS-related cachexia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Von Roenn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Armstrong</forename><forename type="middle">D</forename><surname>Kotler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Cohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Klimas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Tchekmedyian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Cone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Weitzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="393" to="399" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Body-composition changes in patients who gain weight while receiving megestrol acetate</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Loprinzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Schaid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Dose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Burnham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="152" to="154" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome</title>
		<author>
			<persName><forename type="first">C</forename><surname>Madeddu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dessì</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Panzone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Serpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Antoni</forename><forename type="middle">G</forename><surname>Cau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Montaldo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Mura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Astara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tanca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Macciò</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="176" to="182" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Busquets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Serpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sirisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toledo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coutinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martínez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Orpí</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>López-Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argilés</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="733" to="737" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Macciò</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Massa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ghiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Santona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Rev Oncog</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="99" to="106R" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Ursodeoxycholic acid treatment in a rat model of cancer cachexia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="31" to="36" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="105" to="109" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Pötsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beadle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="149" to="158" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Tessitore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Baccino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem J</title>
		<imprint>
			<biblScope unit="volume">241</biblScope>
			<biblScope unit="page" from="153" to="159" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Effect of megestrol acetate on weight loss induced by tumour necrosis factor alpha and a cachexiainducing tumour (MAC16) in NMRI mice</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Tisdale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="420" to="424" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Mccarthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Crowder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dryden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">265</biblScope>
			<biblScope unit="page" from="99" to="102" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bauhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Witte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Celik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lemmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lorenz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Langenbecks Arch Surg</title>
		<imprint>
			<biblScope unit="volume">386</biblScope>
			<biblScope unit="page" from="132" to="140" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Leśniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bała</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jaeschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krzakowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pol Arch Med Wewn</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="636" to="644" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Megestrol acetate-induced differentiation of 3 T3-L1 adipocytes in vitro</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Hamburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Parnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Shantz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Aisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="76" to="78" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Effects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependency</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Helle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lundgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Geisler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ekse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Holly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Lønning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1070" to="1075" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Kazemi-Bajestani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Becher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fassbender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Baracos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="95" to="104" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Monitoring autophagic degradation of p62/SQSTM1</title>
		<author>
			<persName><forename type="first">G1</forename><surname>Bjørkøy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lamark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pankiv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Øvervatn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Johansen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods Enzymol</title>
		<imprint>
			<biblScope unit="volume">452</biblScope>
			<biblScope unit="page" from="181" to="197" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lippai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lőw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Res Int</title>
		<imprint>
			<biblScope unit="page">832704</biblScope>
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhatnagar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mishra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Srivastava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Darnay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1248" to="1259" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Activation of Ca2 + Àdependent proteolysis in skeletal muscle and heart in cancer cachexia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Tullio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Baccino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Melloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="946" to="950" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Turnover rates of muscle protein in cardiac and skeletal muscles of dog, fowl, rat and mouse: turnover rate related to muscle function</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Earl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Laurent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Everett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bonnin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Sparrow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aust J Exp Biol Med Sci</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="265" to="277" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Expression of TRAF6 and proinflammatory cytokines through activation of TLR2, TLR4, NOD1, and NOD2 in human periodontal ligament fibroblasts</title>
		<author>
			<persName><forename type="first">L</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">D</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Oral Biol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="1064" to="1072" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Flach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="3412" to="3418" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Elkina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beadle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="160" to="166" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajs</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="315" to="316" />
			<date type="published" when="2015">2015. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
